Big Pharma’s Big Problems: Insights From Novo Holdings CEO

The State Of Health Care According To Kasim Kutay

Novo Holdings CEO Kasim Kutay discusses today’s financing challenges and tomorrows big pharma pipeline problems in an exclusive interview. Despite turbulent times, he is positive about the future of health care.

Kutay Kasim 2023
Kasim Kutay • Source: Novo Nordisk Foundation

The biotech sector is in rude health despite concerns about raising funds. Its fortunes will improve further over the next five or six years as a number of big pharma players look to deal with feeble growth rates and less-than-compelling pipelines. 

That is the view of Kasim Kutay, the CEO of Novo Holdings, who recently spoke to In Vivo during an...

More from Business Strategy

More from In Vivo